Idebenone Treatment in Patients with OPA1-Dominant Optic Atrophy: A Prospective Phase 2 Trial

References

• Barboni P, Valentino ML, La Morgia C, et al. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain. 2013;136(2):e231–e231. doi:10.1093/brain/aws280.
   PubMedGoogle Scholar
• Yu-Wai-Man P, Shankar SP, Biousse V, et al. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies. Ophthalmology. 2011;118(3):558–563. doi:10.1016/j.ophtha.2010.07.029.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P, Griffiths PG, Burke A, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010;117(8):1538. doi:10.1016/j.ophtha.2009.12.038.
   PubMed Web of Science ®Google Scholar
• La Morgia C, Carbonelli M, Barboni P, Sadun AA, Carelli V. Medical management of hereditary optic neuropathies. Front Neurol. 2014;5(July):1–7. doi:10.3389/fneur.2014.00141.
   PubMedGoogle Scholar
• Cohn AC, Toomes C, Potter C, et al. Autosomal dominant optic atrophy: penetrance and expressivity in patients with OPA1 mutations. Am J Ophthalmol. 2007;143(4):656–662.e1. doi:10.1016/J.AJO.2006.12.038.
   PubMed Web of Science ®Google Scholar
• Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23(1):53–89. doi:10.1016/J.PRETEYERES.2003.10.003.
   PubMed Web of Science ®Google Scholar
• Puomila A, Huoponen K, Mäntyjärvi M, et al. Dominant optic atrophy: correlation between clinical and molecular genetic studies. Acta Ophthalmol Scand. 2005;83(3):337–346. doi:10.1111/J.1600-0420.2005.00448.X.
   PubMedGoogle Scholar
• Del Dotto V, Fogazza M, Lenaers G, Rugolo M, Carelli V, Zanna C. OPA1: how much do we know to approach therapy? Pharmacol Res. 2018;131:199–210. doi:10.1016/J.PHRS.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies – disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30(2–2):81. doi:10.1016/J.PRETEYERES.2010.11.002.
   PubMed Web of Science ®Google Scholar
• Votruba M, Moore AT, Bhattacharya SS, Votruba S, Bhattacharya MS, Votruba M. Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. J Med Genet. 1998;35(10):793–800. doi:10.1136/JMG.35.10.793.
   PubMed Web of Science ®Google Scholar
• Votruba M, Fitzke V, Holder GE, Carter A, Bhattacharya SS, Moore AT. Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol. 1998;116(3):351–358. doi:10.1001/ARCHOPHT.116.3.351.
   PubMedGoogle Scholar
• Johnston RL, Seller MJ, Behnam JT, Burdon MA, Spalton DJ. Dominant optic atrophy: refining the clinical diagnostic criteria in light of genetic linkage studies1. Ophthalmology. 1999;106(1):123–128. doi:10.1016/S0161-6420(99)90013-1.
   PubMed Web of Science ®Google Scholar
• Eliott D, Traboulsi EI, Maumenee IH. Visual prognosis in autosomal dominant optic atrophy (Kjer type). Am J Ophthalmol. 1993;115(3):360–367. doi:10.1016/S0002-9394(14)73589-5.
   PubMed Web of Science ®Google Scholar
• Kjer B, Eiberg H, Kjer P, Rosenberg T. Dominant optic atrophy mapped to chromosome 3q region. Acta Ophthalmol Scand. 1996;74(1):3–7. doi:10.1111/J.1600-0420.1996.TB00672.X.
   PubMedGoogle Scholar
• Cohn AC, Toomes C, Hewitt AW, et al. The natural history of OPA1-related autosomal dominant optic atrophy. Br J Ophthalmol. 2008;92(10):1333–1336. doi:10.1136/bjo.2007.134726.
   PubMed Web of Science ®Google Scholar
• Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain. 2008;131(2):352–367. doi:10.1093/brain/awm335.
   PubMedGoogle Scholar
• Romagnoli M, La Morgia C, Carbonelli M, et al. Idebenone increases chance of stabilization/recovery of visual acuity in OPA1-dominant optic atrophy. Ann Clin Transl Neurol. 2020;7(4):590–594. doi:10.1002/acn3.51026.
   PubMed Web of Science ®Google Scholar
• Giorgio V, Petronilli V, Ghelli A, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta. 2012;1817(2):363. doi:10.1016/J.BBABIO.2011.10.012.
   PubMed Web of Science ®Google Scholar
• Jaber S, Polster BM. Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?J Bioenerg Biomembr. 2015;47:111. doi:10.1007/S10863-014-9571-Y.
   PubMed Web of Science ®Google Scholar
• Raxone | European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/raxone#authorisation-details-section. Accessed March 5, 2022.
   Google Scholar
• Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011;134(9):2677–2686. doi:10.1093/brain/awr170.
   PubMedGoogle Scholar
• Carelli V, Carbonelli M, De Coo IF, et al. International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. J Neuro-Ophthalmol. 2017;37(4):371–381. doi:10.1097/WNO.0000000000000570.
   PubMed Web of Science ®Google Scholar
• Told R, Baratsits M, Garhöfer G, Schmetterer L. ETDRS (early treatment diabetic retinopathy study)-visus. Der Ophthalmol. 2013;110(10):960–965. doi:10.1007/S00347-013-2813-2.
   Google Scholar
• Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91–96. doi:10.1016/0002-9394(82)90197-0.
   PubMed Web of Science ®Google Scholar
• Pelli DG, Robson JG, Wilkins AJ. The DESIGN of a NEW LETTER CHART for MEASURING CONTRAST SENSITIVITY. Clin Vision Sci. 1988;2:187–199.
   Google Scholar
• Subei AM, Eggenberger ER. Optical coherence tomography: another useful tool in a neuro- ophthalmologist’s armamentarium. Curr Opin Ophthalmol. 2009;20(6):462–466. doi:10.1097/ICU.0B013E3283313D4E.
   PubMed Web of Science ®Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-list-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. doi:10.1001/ARCHOPHT.119.7.1050.
   PubMed Web of Science ®Google Scholar
• Franke GH, Esser J, Voigtländer A, Mähner N Der National Eye Institute Visual Function Questionnaire (NEI-VFQ)–Erste Ergebnisse zur psychometrischen Überprüfung eines Verfahrens zur Erfassung der Lebensqualität bei Sehbeeinträchtigten. Zeitschrift für Medizinische Psychol. Published online 1998:178–184. https://www.researchgate.net/publication/310595360_Der_National_Eye_Institute_Visual_Function_Questionnaire_NEI-VFQ_-_Erste_Ergebnisse_zur_psychometrischen_Uberprufung_eines_Verfahrens_zur_Erfassung_der_Lebensqualitat_bei_Sehbeeintrachtigten. Accessed June 3, 2022.
   Google Scholar
• Mangione C. The national eye institute 25-item visual function questionnaire (VFQ-25). https://www.nei.nih.gov/learn-about-eye-health/outreach-campaigns-and-resources/outreach-materials/visual-function-questionnaire-25. Published 2000. Accessed June 3, 2022.
   Google Scholar
• RIS - Arzneimittelgesetz - Bundesrecht konsolidiert, Fassung vom 30.04.2022. https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10010441. Accessed April 30, 2022.
   Google Scholar
• Cornille K, Milea D, Amati-Bonneau P, et al. Reversible optic neuropathy with OPA1 exon 5b mutation. Ann Neurol. 2008;63(5):667–671. doi:10.1002/ANA.21376.
   PubMed Web of Science ®Google Scholar
• Pemp B, Mitsch C, Kircher K, Reitner A. Changes in visual function and correlations with inner retinal structure in acute and chronic Leber’s hereditary optic neuropathy patients after treatment with idebenone. J Clin Med. 2021;10(1):1–13. doi:10.3390/JCM10010151.
   Web of Science ®Google Scholar
• Eiberg H, Kjer B, Kjer P, Rosenberg T. Dominant optic atrophy (OPA1) mapped to chromosome 3q region. I. Linkage analysis. Hum Mol Genet. 1994;3(6):977–980. doi:10.1093/HMG/3.6.977.
   PubMed Web of Science ®Google Scholar
• Brown J. Clinical and genetic analysis of a family affected with dominant optic atrophy (OPA1). Arch Ophthalmol. 1997;115(1):95–99. doi:10.1001/ARCHOPHT.1997.01100150097016.
   PubMedGoogle Scholar
• Eckmann-Hansen C, Bek T, Sander B, Larsen M. Vision-related quality of life and visual ability in patients with autosomal dominant optic atrophy. Acta Ophthalmol. 2022;100(7):797–804. Published online 2022. doi:10.1111/AOS.15102.
   PubMed Web of Science ®Google Scholar